The global transdermal patch market, valued at $7.8 billion in 2023, is on a trajectory to reach nearly $10.95 billion by 2030, with pain patches leading the charge. This growth is not merely a testament to the convenience of transdermal drug delivery but also its critical role in addressing public health challenges, such as managing chronic pain in aging populations and providing a safer alternative to traditional opioid use. The abuse-deterrent opioid segment, though still in its nascent stages, is expected to more than double between 2024 and 2030, fueled by regulatory pressures, clinical demand, and technological advancements.

Among the companies making significant strides in this space is Nutriband Inc. (NASDAQ: NTRB), which is pioneering the opioid pain management sector with its AVERSA Fentanyl patch. This innovative product is designed to deter abuse, misuse, and accidental exposure, leveraging Nutriband’s proprietary AVERSA technology. With a potential peak annual US sales forecast between 80 million and 200 million dollars, AVERSA Fentanyl represents a significant advancement in opioid safety. Nutriband’s progress is further underscored by its revenue generation and strategic partnerships, positioning it as a key player in the transdermal drug delivery market.

Collegium Pharmaceutical, Inc. (Nasdaq: COLL) is another company making waves in the pain and neuropsychiatry treatment markets. With a 23 percent year-over-year increase in net revenue in the first quarter of 2025, Collegium’s consistent growth and expanding product reach highlight its strong position in the biopharma sector. The company’s focus on responsibly managed pain treatments and a growing ADHD franchise offers a diversified growth engine, appealing to investors looking for profitable, commercial-stage biotech opportunities.

Assertio Holdings, Inc. (Nasdaq: ASRT) is transitioning into a focused specialty pharmaceutical company, shedding legacy risks and strengthening its commercial platform. With sales from growth assets like Rolvedon and Sympazan outperforming expectations, Assertio is poised for near-term revenue expansion. The company’s efforts to streamline operations and reduce legal exposure have cleared the path for a renewed focus on high-potential assets and business development.

Aquestive Therapeutics, Inc. (Nasdaq: AQST) is advancing innovative delivery technologies for complex molecules, with its late-stage proprietary candidate, Anaphylm, nearing regulatory approval. Aquestive’s focus on non-invasive treatments for severe allergic reactions and its clear commercial strategy position it as a promising player in the specialty pharmaceutical delivery space.

These companies exemplify the innovative spirit driving the future of pain therapy, offering safer, more effective alternatives to traditional treatments. Their progress not only highlights the potential of the transdermal patch market but also underscores the importance of innovation in addressing some of the most pressing challenges in healthcare today.

This news story relied on content distributed by None. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Innovative Small-Cap Biopharma Companies Lead the Future of Pain Therapy.